Dr. John Cush RheumNow
5 years 3 months ago
Retrospective study of 258 IBD patients, 17% had MRI sacroiliitis (73% w/ bone marrow edema. Sacroiliitis was significantly associated w/ Female gender, back pain, and later age of CD diagnosis. >two-thirds of these pts never seen a rheumatologist. https://t.co/HYhAU6aRIf
Dr. John Cush RheumNow
5 years 3 months ago
GFR decline in 2269 RA pts (15 mos F/U) - Most RA had a GFR decline w/ age. Pts w/ higher DAS28-CRP had more GFR decline. Pts in remission/LDAS had a slower rate of eGFR loss (−0.817 vs −1.283 cc/min per year; P < 0.001) https://t.co/rnIc080xYb
Rituximab (RTX) has been in the news a lot lately; more surprisingly for its potential benefits in progressive systemic sclerosis (SSc).
Ebata and colleagues have published the results of a double-blind, randomised, placebo-controlled trial comparing intravenous RTX to placebo in 56 SSc patients. Patients had to have a modified Rodnan Skin Score (mRSS) of 10 or more. The primary endpoint was the change in mRSS at 24 weeks.
The American College of Rheumatology (ACR) has released an updated position statement on patient safety and site of service for biologics outlining several reasons why the ACR strongly believes infusions should be administered in a monitored health care setting with onsite supervision by a provider with appropriate training in biologic infusions.
Dr. John Cush RheumNow
5 years 3 months ago
Analysis of Ph 3 data Tofacitinib in Ulcerative Colitis shows no increase in Cancer; rates equal to that seen w/ Tofa in RA, PsA & other biologics in UC. In 1124 pts (2576 PtYrs) there were 20 cancers, excluding NMSC (IR, 0.75; 0.46–1.16) https://t.co/xiTIKYAtyY
Dr. John Cush RheumNow
5 years 3 months ago
Blindness with Tocilizumab in GCA: Is it a Worry?
https://t.co/PJYap294jm https://t.co/q1izGlH68j
Dr. John Cush RheumNow
5 years 3 months ago
EULAR 2021 Lupus Panel
Drs. Cush, Dao, Pope, Dein and Yusof discuss a number of lupus presentations as well as abstracts presented at the virtual EULAR 2021 meeting. Lupus nephritis and treat-to-remission presentations were discussed by the panel.
https://t.co/yUEXTOatpR
Dr. John Cush RheumNow
5 years 3 months ago
Alcohol abuse worsens psoriasis. Prospective study of 266 Psoriasis pts (1/2 biologics; 1/2 ; conventional Rx). Poorer outcomes predicted by alcohol abuse (CAGE score) (regression co-efficient 1.40), obesity (1.84) & conventional Rx (4.39) https://t.co/CJGTT0HoV2
Dr. John Cush RheumNow
5 years 3 months ago
Which patients with psoriasis are at risk to develop PsA?
https://t.co/5sj5HSnke3 https://t.co/vxOHIUrevd
Dr. Jack Cush reviews this week’s news and journal reports featured on RheumNow.com.
Dr. John Cush RheumNow
5 years 3 months ago
FDA has granted emergency use authorization (EUA) for Actemra (tocilizumab) us in treating hospitalized COVID-19 (adults and kids) patients on steroids and who require, supplemental oxygen, mechanical ventilation, or ECMO https://t.co/YAVfbykcti https://t.co/d7pS1lUXpa
Dr. John Cush RheumNow
5 years 3 months ago
The FDA has informed Abbvie that their supplemental application for new indications (PsA and AS) for upadacitinib (Rinvoq) has been delayed; the FDA citing its ongoing review of tofacitinibs safety concerns stemming from the ORAL Surveillance RA study https://t.co/sSJyVtQNYu
Dr. John Cush RheumNow
5 years 3 months ago
Danish population study shows that all cause mortality in GCA is increased 49%,(RR 1.49; CI1.36-1.64) after 1 year but less so at 10 years (RR 1.03: 1.00-1.05). Deaths usually due to infectious, endocrine, cardiovascular, GI diseases https://t.co/p36zDskf6y
